Annual CFF
$4.39 M
-$3.09 M-41.34%
December 31, 2024
Summary
- As of March 13, 2025, VIR annual cash flow from financing activities is $4.39 million, with the most recent change of -$3.09 million (-41.34%) on December 31, 2024.
- During the last 3 years, VIR annual CFF has fallen by -$95.94 million (-95.63%).
- VIR annual CFF is now -99.17% below its all-time high of $529.47 million, reached on December 31, 2020.
Performance
VIR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$1.26 M
+$1.23 M+3974.19%
December 31, 2024
Summary
- As of March 13, 2025, VIR quarterly cash flow from financing activities is $1.26 million, with the most recent change of +$1.23 million (+3974.19%) on December 31, 2024.
- Over the past year, VIR quarterly CFF has dropped by -$1.68 million (-57.07%).
- VIR quarterly CFF is now -99.61% below its all-time high of $324.31 million, reached on September 30, 2020.
Performance
VIR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$4.39 M
-$417.00 K-8.68%
December 31, 2024
Summary
- As of March 13, 2025, VIR TTM cash flow from financing activities is $4.39 million, with the most recent change of -$417.00 thousand (-8.68%) on December 31, 2024.
- Over the past year, VIR TTM CFF has dropped by -$663.00 thousand (-13.13%).
- VIR TTM CFF is now -99.33% below its all-time high of $659.83 million, reached on September 30, 2020.
Performance
VIR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VIR Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -41.3% | -57.1% | -13.1% |
| 3 y3 years | -95.6% | -46.1% | -53.4% |
| 5 y5 years | -99.0% | -46.1% | -53.4% |
VIR Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -95.6% | at low | -95.4% | +3974.2% | -95.6% | at low |
| 5 y | 5-year | -99.2% | at low | -99.6% | +587.6% | -99.3% | at low |
| alltime | all time | -99.2% | at low | -99.6% | +587.6% | -99.3% | at low |
Vir Biotechnology Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $4.39 M(-41.3%) | $1.26 M(+3974.2%) | $4.39 M(-8.7%) |
| Sep 2024 | - | $31.00 K(-98.9%) | $4.80 M(-4.9%) |
| Jun 2024 | - | $2.94 M(+1835.5%) | $5.05 M(-4.5%) |
| Mar 2024 | - | $152.00 K(-91.0%) | $5.29 M(-29.3%) |
| Dec 2023 | $7.48 M(-78.5%) | $1.68 M(+506.5%) | $7.48 M(-4.2%) |
| Sep 2023 | - | $277.00 K(-91.3%) | $7.81 M(-17.9%) |
| Jun 2023 | - | $3.18 M(+35.6%) | $9.52 M(+1.1%) |
| Mar 2023 | - | $2.34 M(+16.6%) | $9.42 M(-72.9%) |
| Dec 2022 | $34.76 M(-65.4%) | $2.01 M(+1.3%) | $34.76 M(-9.5%) |
| Sep 2022 | - | $1.99 M(-35.6%) | $38.42 M(-4.1%) |
| Jun 2022 | - | $3.08 M(-88.9%) | $40.06 M(-1.1%) |
| Mar 2022 | - | $27.68 M(+388.3%) | $40.51 M(-59.6%) |
| Dec 2021 | $100.33 M | $5.67 M(+56.2%) | $100.33 M(+6.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $3.63 M(+2.8%) | $94.40 M(-77.3%) |
| Jun 2021 | - | $3.53 M(-96.0%) | $415.08 M(-32.7%) |
| Mar 2021 | - | $87.50 M(<-9900.0%) | $616.89 M(+16.5%) |
| Dec 2020 | $529.47 M(+17.9%) | -$259.00 K(-100.1%) | $529.47 M(-19.8%) |
| Sep 2020 | - | $324.31 M(+57.9%) | $659.83 M(+95.6%) |
| Jun 2020 | - | $205.34 M(>+9900.0%) | $337.26 M(+155.7%) |
| Mar 2020 | - | $85.00 K(-99.9%) | $131.92 M(-70.6%) |
| Dec 2019 | $449.24 M(+1698.6%) | $130.10 M(+7411.5%) | $449.24 M(+40.8%) |
| Sep 2019 | - | $1.73 M(>+9900.0%) | $319.14 M(+0.5%) |
| Jun 2019 | - | $3000.00(-100.0%) | $317.41 M(+0.0%) |
| Mar 2019 | - | $317.41 M | $317.41 M |
| Dec 2018 | $24.98 M(-90.8%) | - | - |
| Dec 2017 | $271.18 M | - | - |
FAQ
- What is Vir Biotechnology annual cash flow from financing activities?
- What is the all time high annual CFF for Vir Biotechnology?
- What is Vir Biotechnology annual CFF year-on-year change?
- What is Vir Biotechnology quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Vir Biotechnology?
- What is Vir Biotechnology quarterly CFF year-on-year change?
- What is Vir Biotechnology TTM cash flow from financing activities?
- What is the all time high TTM CFF for Vir Biotechnology?
- What is Vir Biotechnology TTM CFF year-on-year change?
What is Vir Biotechnology annual cash flow from financing activities?
The current annual CFF of VIR is $4.39 M
What is the all time high annual CFF for Vir Biotechnology?
Vir Biotechnology all-time high annual cash flow from financing activities is $529.47 M
What is Vir Biotechnology annual CFF year-on-year change?
Over the past year, VIR annual cash flow from financing activities has changed by -$3.09 M (-41.34%)
What is Vir Biotechnology quarterly cash flow from financing activities?
The current quarterly CFF of VIR is $1.26 M
What is the all time high quarterly CFF for Vir Biotechnology?
Vir Biotechnology all-time high quarterly cash flow from financing activities is $324.31 M
What is Vir Biotechnology quarterly CFF year-on-year change?
Over the past year, VIR quarterly cash flow from financing activities has changed by -$1.68 M (-57.07%)
What is Vir Biotechnology TTM cash flow from financing activities?
The current TTM CFF of VIR is $4.39 M
What is the all time high TTM CFF for Vir Biotechnology?
Vir Biotechnology all-time high TTM cash flow from financing activities is $659.83 M
What is Vir Biotechnology TTM CFF year-on-year change?
Over the past year, VIR TTM cash flow from financing activities has changed by -$663.00 K (-13.13%)